These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Among the devils in the details are protease sequence, susceptibility, and structure in CRF02_AG viruses. Katzenstein D; Ogden R Clin Infect Dis; 2005 Jul; 41(2):252-4. PubMed ID: 15983924 [No Abstract] [Full Text] [Related]
6. Synthesis and antiviral activities of novel N-alkoxy-arylsulfonamide-based HIV protease inhibitors. Sherrill RG; Furfine ES; Hazen RJ; Miller JF; Reynolds DJ; Sammond DM; Spaltenstein A; Wheelan P; Wright LL Bioorg Med Chem Lett; 2005 Aug; 15(15):3560-4. PubMed ID: 15975788 [TBL] [Abstract][Full Text] [Related]
10. Amprenavir resistance imparted by the I50V mutation in HIV-1 protease can be suppressed by the N88S mutation. Lam E; Parkin NT Clin Infect Dis; 2003 Nov; 37(9):1273-4. PubMed ID: 14557976 [No Abstract] [Full Text] [Related]
11. Novel nonpeptidic inhibitors of HIV-1 protease obtained via a new multicomponent chemistry strategy. Yehia NA; Antuch W; Beck B; Hess S; Schauer-Vukasinović V; Almstetter M; Furer P; Herdtweck E; Dömling A Bioorg Med Chem Lett; 2004 Jun; 14(12):3121-5. PubMed ID: 15149657 [TBL] [Abstract][Full Text] [Related]
12. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach. Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839 [TBL] [Abstract][Full Text] [Related]
13. Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors. Calugi C; Guarna A; Trabocchi A Eur J Med Chem; 2014 Sep; 84():444-53. PubMed ID: 25042102 [TBL] [Abstract][Full Text] [Related]
14. A mechanistic study of 3-aminoindazole cyclic urea HIV-1 protease inhibitors using comparative QSAR. Garg R; Bhhatarai B Bioorg Med Chem; 2004 Nov; 12(22):5819-31. PubMed ID: 15498658 [TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands. Qiu X; Zhao GD; Tang LQ; Liu ZP Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846 [TBL] [Abstract][Full Text] [Related]
17. Peptidomimetic inhibitors complexed with HIV-1 protease: crystallisation for X-ray diffraction studies. Dohnálek J; Hasek J; Brynda J; Fábry M; Sedlácek J; Konvalinka J; Hradilek M; Soucek M; Adams MJ; Naylor CE Gen Physiol Biophys; 1998 Jun; 17 Suppl 1():9-11. PubMed ID: 9789742 [No Abstract] [Full Text] [Related]
18. Evaluation of triazolamers as active site inhibitors of HIV-1 protease. Jochim AL; Miller SE; Angelo NG; Arora PS Bioorg Med Chem Lett; 2009 Nov; 19(21):6023-6. PubMed ID: 19800230 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the substrate envelope hypothesis for inhibitors of HIV-1 protease. Chellappan S; Kairys V; Fernandes MX; Schiffer C; Gilson MK Proteins; 2007 Aug; 68(2):561-7. PubMed ID: 17474129 [TBL] [Abstract][Full Text] [Related]
20. Target-selective photodegradation of HIV-1 protease and inhibition of HIV-1 replication in living cells by designed fullerene-sugar hybrids. Tanimoto S; Sakai S; Kudo E; Okada S; Matsumura S; Takahashi D; Toshima K Chem Asian J; 2012 May; 7(5):911-4. PubMed ID: 22378594 [No Abstract] [Full Text] [Related] [Next] [New Search]